# Fexuprazan for Prevention of Upper Gastrointestinal Bleeding in High Bleeding Risk Patients Receiving Dual Antiplatelet Therapy

> **NCT07479056** · NA · RECRUITING · sponsor: **SUK MIN SEO** · enrollment: 400 (estimated)

## Conditions studied

- Acute Coronary Syndromes (ACS)
- Coronary Artery Disease (CAD)

## Interventions

- **DRUG:** Fexuprazan 40mg
- **DRUG:** Lansoprazole 30mg

## Key facts

- **NCT ID:** NCT07479056
- **Lead sponsor:** SUK MIN SEO
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-24
- **Primary completion:** 2028-04-30
- **Final completion:** 2028-12-31
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2026-04-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07479056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07479056, "Fexuprazan for Prevention of Upper Gastrointestinal Bleeding in High Bleeding Risk Patients Receiving Dual Antiplatelet Therapy". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT07479056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*